Difesa Capital Management’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Difesa Capital Management’s Portfolio PBAXU Stock Details PBAXU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-125,000	Closed	-$1.26M	–	268
2022 Q3	$1.26M	Hold	125,000	–	–	0.64%	49
2022 Q2	$1.26M	Hold	125,000	–	–	0.72%	49
2022 Q1	$1.26M	Hold	125,000	–	–	0.64%	50
2021 Q4	$1.26M	Buy	+125,000	New	+$1.27M	0.86%	41

Other funds holding PBAXU

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Difesa Capital Management's PBAXU Position: Q4 2022 in Review

Difesa Capital Management sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q4 2022, closing a stake of 125,000 shares — an estimated $1.26M sold.

Difesa Capital Management first reported a position in PBAXU in Q4 2021 and held it in 4 quarters. The position peaked at $1.26M in Q3 2022. 3 funds tracked by Wall St. Rank hold PBAXU as of Q4 2022.

Difesa Capital Management reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Difesa Capital Management sold 125,000 Phoenix Biotech Acquisition Corp. Unit shares in Q4 2022, an estimated $1.26M.
Difesa Capital Management first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
Difesa Capital Management's Phoenix Biotech Acquisition Corp. Unit position peaked at $1.26M in Q3 2022.
3 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q4 2022.

Based on Difesa Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.